MTOR and endometrial cancer: The PI3K/AKT/mammalian target of rapamycin (mTOR) pathway is considered to be a pivotal intracellular signaling pathway and its hyperactivity is correlated with tumor progression in a wide assortment of cancers, counting breast, gastric, ovarian, colorectal, prostate, glioblastoma, and endometrial cancers [89].